Two hepatitis C virus (HCV) combination treatments, Technivie (ombitasvir, paritaprevir, ritonavir) and Viekira XR (dasabuvir sodium, ombitasvir, paritaprevir, ritonavir), have been discontinued by AbbVie, according to the Food and Drug Administration (FDA). The discontinuation is voluntary and is not related to product quality, safety or efficacy.
Technivie is indicated in combination with ribavirin for the treatment of chronic HCV genotype 4 (GT4) infection without cirrhosis or with compensated cirrhosis. Approved in 2015, Technivie was the first all-oral, interferon-free, direct-acting antiviral treatment indicated for adults with GT4 chronic HCV infection.
Viekira XR, approved in 2016, is indicated for the treatment of chronic HCV genotype 1a (in combination with ribavirin) or 1b infection without cirrhosis or with compensated cirrhosis. The product is an extended-release formulation of the active ingredients found in Viekira Pak.
Both products are estimated to be available until January 1, 2019.
A comparative table of pharmacological therapies for HCV infection treatment can be found here.
For more information call (800) 255-5162 or visit FDA.gov.
This article originally appeared on MPR